BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 2014;84:1-11. [PMID: 24754973 DOI: 10.1016/j.phrs.2014.04.004] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Aaseth J, Roer GE, Lien L, Bjørklund G. Is there a relationship between PTSD and complicated obesity? A review of the literature. Biomed Pharmacother 2019;117:108834. [PMID: 31177066 DOI: 10.1016/j.biopha.2019.108834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Wilding JP. Combination therapy for obesity. J Psychopharmacol 2017;31:1503-8. [PMID: 29132230 DOI: 10.1177/0269881117737401] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
3 Rebello CJ, Greenway FL. Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings. Adv Ther 2016;33:1853-66. [PMID: 27718159 DOI: 10.1007/s12325-016-0414-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
4 Casu A, Bilal A, Pratley RE; Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON). Pharmacological therapies to address obesity in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020;27:194-206. [PMID: 32618631 DOI: 10.1097/MED.0000000000000555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Gupta A, Osadchiy V, Mayer EA. Brain-gut-microbiome interactions in obesity and food addiction. Nat Rev Gastroenterol Hepatol. 2020;17:655-672. [PMID: 32855515 DOI: 10.1038/s41575-020-0341-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 23.0] [Reference Citation Analysis]
6 Subramaniapillai M, McIntyre RS. A review of the neurobiology of obesity and the available pharmacotherapies. CNS Spectr 2017;22:29-38. [PMID: 29350126 DOI: 10.1017/S1092852917000839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
7 Li Y, Tao Y, Gao X, Yu F. Case Report: Bilateral Ciliary Body Detachment in a Patient Taking Oral Diet Pills. Optom Vis Sci 2021;98:876-80. [PMID: 34460449 DOI: 10.1097/OPX.0000000000001743] [Reference Citation Analysis]
8 Rees R, Seyfoddin A. The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review. J Pharm Policy Pract 2017;10:20. [PMID: 28702203 DOI: 10.1186/s40545-017-0109-7] [Reference Citation Analysis]
9 Kahan S, Fujioka K. Obesity Pharmacotherapy in Patients With Type 2 Diabetes. Diabetes Spectr 2017;30:250-7. [PMID: 29151715 DOI: 10.2337/ds17-0044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
10 Mooney LJ, Hillhouse MP, Thomas C, Ang A, Sharma G, Terry G, Chang L, Walker R, Trivedi M, Croteau D, Sparenborg S, Ling W. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. J Addict Med 2016;10:236-43. [PMID: 27379819 DOI: 10.1097/ADM.0000000000000218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Meneguetti BT, Cardoso MH, Ribeiro CF, Felício MR, Pinto IB, Santos NC, Carvalho CM, Franco OL. Neuropeptide receptors as potential pharmacological targets for obesity. Pharmacology & Therapeutics 2019;196:59-78. [DOI: 10.1016/j.pharmthera.2018.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Saunders KH, Igel LI, Aronne LJ. An update on naltrexone/bupropion extended-release in the treatment of obesity. Expert Opinion on Pharmacotherapy 2016;17:2235-42. [DOI: 10.1080/14656566.2016.1244527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bonsu DOM, Afoakwah C, Aguilar-caballos MDLP. Counterfeit formulations: analytical perspective on anorectics. Forensic Toxicol 2021;39:1-25. [DOI: 10.1007/s11419-020-00564-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Siamidi A, Dedeloudi A, Vlachou M. Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures. Polymers (Basel) 2021;13:1456. [PMID: 33946250 DOI: 10.3390/polym13091456] [Reference Citation Analysis]
15 Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-47. [PMID: 27773782 DOI: 10.1016/j.pharmthera.2016.10.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
16 Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, Goldberg IJ, Schwartzbard AZ. Cardiovascular Effects of the New Weight Loss Agents. Journal of the American College of Cardiology 2016;68:849-59. [DOI: 10.1016/j.jacc.2016.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
17 Karlsson HK, Tuominen L, Helin S, Salminen P, Nuutila P, Nummenmaa L. Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery. Transl Psychiatry 2021;11:259. [PMID: 33934103 DOI: 10.1038/s41398-021-01370-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Verhaegen AA, Van Gaal LF. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. J Endocrinol Invest 2017;40:1165-74. [PMID: 28660606 DOI: 10.1007/s40618-017-0719-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
19 Dumas SN, Ntambi JM. A Discussion on the Relationship between Skin Lipid Metabolism and Whole-Body Glucose and Lipid Metabolism: Systematic Review. J Cell Signal 2018;3:189. [PMID: 30474082 DOI: 10.4172/2576-1471.1000189] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Mason AE, Lustig RH, Brown RR, Acree M, Bacchetti P, Moran PJ, Dallman M, Laraia B, Adler N, Hecht FM, Daubenmier J, Epel ES. Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial. Appetite 2015;91:311-20. [PMID: 25931433 DOI: 10.1016/j.appet.2015.04.062] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
21 Boswell RG, Kober H. Food cue reactivity and craving predict eating and weight gain: a meta-analytic review. Obes Rev 2016;17:159-77. [PMID: 26644270 DOI: 10.1111/obr.12354] [Cited by in Crossref: 264] [Cited by in F6Publishing: 228] [Article Influence: 37.7] [Reference Citation Analysis]
22 Wang GJ, Zhao J, Tomasi D, Kojori ES, Wang R, Wiers CE, Caparelli EC, Volkow ND. Effect of combined naltrexone and bupropion therapy on the brain's functional connectivity. Int J Obes (Lond) 2018;42:1890-9. [PMID: 29535451 DOI: 10.1038/s41366-018-0040-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
23 Crinò A, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes 2018;11:579-93. [PMID: 30323638 DOI: 10.2147/DMSO.S141352] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
24 Conceição EPS, Reynolds CA, Morrison SF, Madden CJ. Activation of Transient Receptor Potential Vanilloid 1 Channels in the Nucleus of the Solitary Tract and Activation of Dynorphin Input to the Median Preoptic Nucleus Contribute to Impaired BAT Thermogenesis in Diet-Induced Obesity. eNeuro 2021;8:ENEURO. [PMID: 33707202 DOI: 10.1523/ENEURO.0048-21.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Verhaegen AA, Van Gaal LF. Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update. Curr Obes Rep 2021;10:1-13. [PMID: 33400222 DOI: 10.1007/s13679-020-00419-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
26 Kahan S, Winston G. Addressing Obesity in Clinical Gynecology Practice. Clinical Obstetrics & Gynecology 2018;61:10-26. [DOI: 10.1097/grf.0000000000000334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Dalton M, Finlayson G, Walsh B, Halseth AE, Duarte C, Blundell JE. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. Int J Obes (Lond) 2017;41:1232-6. [PMID: 28373674 DOI: 10.1038/ijo.2017.89] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
28 Zhou Y, Leri F, Low MJ, Kreek MJ. Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice. Pharmacol Biochem Behav 2019;181:28-36. [PMID: 30991059 DOI: 10.1016/j.pbb.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Benaiges D, Pedro-botet J, Flores-le Roux JA, Climent E, Goday A. Pasado, presente y futuro de la farmacoterapia para la obesidad. Clínica e Investigación en Arteriosclerosis 2017;29:256-64. [DOI: 10.1016/j.arteri.2017.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
30 Natsis M, Antza C, Doundoulakis I, Stabouli S, Kotsis V. Hypertension in Obesity: Novel Insights. Curr Hypertens Rev 2020;16:30-6. [PMID: 30987571 DOI: 10.2174/1573402115666190415154603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
31 Simonds SE, Pryor JT, Koegler FH, Buch-Rasmussen AS, Kelly LE, Grove KL, Cowley MA. Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice. Diabetes 2019;68:683-95. [PMID: 30674622 DOI: 10.2337/db18-1149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Jackson VM, Breen DM, Fortin J, Liou A, Kuzmiski JB, Loomis AK, Rives M, Shah B, Carpino PA. Latest approaches for the treatment of obesity. Expert Opinion on Drug Discovery 2015;10:825-39. [DOI: 10.1517/17460441.2015.1044966] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
33 Kane JA, Mehmood T, Munir I, Kamran H, Kariyanna PT, Zhyvotovska A, Yusupov D, Suleman UJ, Gustafson DR, McFarlane SI. Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis. Int J Clin Res Trials 2019;4:131. [PMID: 31058246 DOI: 10.15344/2456-8007/2019/131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
34 Guerdjikova AI, Walsh B, Shan K, Halseth AE, Dunayevich E, McElroy SL. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Adv Ther 2017;34:2307-15. [PMID: 28918581 DOI: 10.1007/s12325-017-0613-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
35 Rueda-Ruzafa L, Cruz F, Cardona D, Hone AJ, Molina-Torres G, Sánchez-Labraca N, Roman P. Opioid system influences gut-brain axis: Dysbiosis and related alterations. Pharmacol Res 2020;159:104928. [PMID: 32504837 DOI: 10.1016/j.phrs.2020.104928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Vardanyan GS, Harutyunyan HS, Aghajanov MI, Vardanyan RS. Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects. Future Med Chem 2020;12:1865-84. [PMID: 33040605 DOI: 10.4155/fmc-2019-0361] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Greig SL, Keating GM. Naltrexone ER/Bupropion ER: A Review in Obesity Management. Drugs 2015;75:1269-80. [DOI: 10.1007/s40265-015-0427-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
38 Apovian CM. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future Cardiology 2016;12:129-38. [DOI: 10.2217/fca.15.79] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
39 Carbone EA, Caroleo M, Rania M, Calabrò G, Staltari FA, de Filippis R, Aloi M, Condoleo F, Arturi F, Segura-Garcia C. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eat Weight Disord 2021;26:779-88. [PMID: 32356145 DOI: 10.1007/s40519-020-00910-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
40 Anker JJ, Nakajima M, Raatz S, Allen S, al'Absi M. Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system. Drug Alcohol Depend 2021;225:108819. [PMID: 34182373 DOI: 10.1016/j.drugalcdep.2021.108819] [Reference Citation Analysis]
41 Scotti L, Monteiro AFM, de Oliveira Viana J, Mendonça Junior FJB, Ishiki HM, Tchouboun EN, Santos R, Scotti MT. Multi-Target Drugs Against Metabolic Disorders. Endocr Metab Immune Disord Drug Targets 2019;19:402-18. [PMID: 30556507 DOI: 10.2174/1871530319666181217123357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Imperatori C, Valenti EM, Della Marca G, Amoroso N, Massullo C, Carbone GA, Maestoso G, Quintiliani MI, Contardi A, Farina B. Coping food craving with neurofeedback. Evaluation of the usefulness of alpha/theta training in a non-clinical sample. International Journal of Psychophysiology 2017;112:89-97. [DOI: 10.1016/j.ijpsycho.2016.11.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
43 Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord 2014;15:329-41. [DOI: 10.1007/s11154-014-9298-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
44 Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39:1188-1196. [PMID: 25896063 DOI: 10.1038/ijo.2015.59] [Cited by in Crossref: 171] [Cited by in F6Publishing: 144] [Article Influence: 24.4] [Reference Citation Analysis]
45 Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes 2016;6:305-12. [PMID: 27477337 DOI: 10.1111/cob.12157] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 May M, Schindler C, Engeli S. Modern pharmacological treatment of obese patients. Ther Adv Endocrinol Metab 2020;11:2042018819897527. [PMID: 32030121 DOI: 10.1177/2042018819897527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
47 San Giovanni CB, Sweeney B, Skelton JA, Kelsey MM, Kelly AS. Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. J Clin Endocrinol Metab 2021;106:2103-13. [PMID: 33901290 DOI: 10.1210/clinem/dgab276] [Reference Citation Analysis]
48 Bojanowska E, Ciosek J. Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior. Curr Neuropharmacol 2016;14:118-42. [PMID: 26549651 DOI: 10.2174/1570159x14666151109103147] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
49 Hocking S, Dear A, Cowley MA. Current and emerging pharmacotherapies for obesity in Australia. Obes Res Clin Pract 2017;11:501-21. [PMID: 28818558 DOI: 10.1016/j.orcp.2017.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Antonelli M, Ferrulli A, Sestito L, Vassallo GA, Tarli C, Mosoni C, Rando MM, Mirijello A, Gasbarrini A, Addolorato G. Alcohol addiction - the safety of available approved treatment options. Expert Opin Drug Saf 2018;17:169-77. [PMID: 29120249 DOI: 10.1080/14740338.2018.1404025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
51 Walter TJ, Navarro M, Thiele TE, Pedersen C, Kampov-Polevoy A, Garbutt JC. A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects. Alcohol Alcohol 2020;55:56-62. [PMID: 31746964 DOI: 10.1093/alcalc/agz076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Karlsson HK, Tuulari JJ, Tuominen L, Hirvonen J, Honka H, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L. Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity. Mol Psychiatry. 2016;21:1057-1062. [PMID: 26460230 DOI: 10.1038/mp.2015.153] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
53 Rodgers R. Bench to bedside in appetite research: Lost in translation? Neuroscience & Biobehavioral Reviews 2017;76:163-73. [DOI: 10.1016/j.neubiorev.2016.08.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
54 Lee SH, Paz-Filho G, Mastronardi C, Licinio J, Wong ML. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry 2016;6:e759. [PMID: 26978741 DOI: 10.1038/tp.2016.25] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
55 Ikeda Y, Funayama T, Tateno A, Fukayama H, Okubo Y, Suzuki H. Bupropion increases activation in nucleus accumbens during anticipation of monetary reward. Psychopharmacology 2019;236:3655-65. [DOI: 10.1007/s00213-019-05337-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
56 Valbrun LP, Zvonarev V. The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior. J Clin Med Res 2020;12:41-63. [PMID: 32095174 DOI: 10.14740/jocmr4066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
57 Kolotkin RL, Chen S, Klassen P, Gilder K, Greenway FL. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity: Quality of life improvement with weight loss. Clinical Obesity 2015;5:237-44. [DOI: 10.1111/cob.12108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
58 Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y, Jarskog F, Zhao M, Fan X. Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia. Front Pharmacol 2018;9:181. [PMID: 29563871 DOI: 10.3389/fphar.2018.00181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Rosa-Gonçalves P, Majerowicz D. Pharmacotherapy of Obesity: Limits and Perspectives. Am J Cardiovasc Drugs 2019;19:349-64. [PMID: 30793263 DOI: 10.1007/s40256-019-00328-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
60 Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev 2021:bnab034. [PMID: 34698815 DOI: 10.1210/endrev/bnab034] [Reference Citation Analysis]
61 Sharfman N, Gilpin NW. The Role of Melanocortin Plasticity in Pain-Related Outcomes After Alcohol Exposure. Front Psychiatry 2021;12:764720. [PMID: 34803772 DOI: 10.3389/fpsyt.2021.764720] [Reference Citation Analysis]
62 Vasiliu O. Current Status of Evidence for a New Diagnosis: Food Addiction-A Literature Review. Front Psychiatry 2021;12:824936. [PMID: 35082706 DOI: 10.3389/fpsyt.2021.824936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
63 Milano W, De Biasio V, Di Munzio W, Foggia G, Capasso A. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocr Metab Immune Disord Drug Targets 2020;20:1232-43. [PMID: 32410565 DOI: 10.2174/1871530320666200515112853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
64 Shah M, Hurt RT, Mundi MS. Phenotypes of Obesity: How it Impacts Management. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0598-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
65 Frank J, Gupta A, Osadchiy V, Mayer EA. Brain-Gut-Microbiome Interactions and Intermittent Fasting in Obesity. Nutrients 2021;13:584. [PMID: 33578763 DOI: 10.3390/nu13020584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocrine Practice 2016;22:1-203. [DOI: 10.4158/ep161365.gl] [Cited by in Crossref: 406] [Cited by in F6Publishing: 172] [Article Influence: 67.7] [Reference Citation Analysis]
67 Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med 2019;7:393. [PMID: 31555707 DOI: 10.21037/atm.2019.07.27] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]